|
Purpose of the guideline：
|
In recent years, the treatment of patients with COVID-19 infection has been a major focus in the medical field. Although a number of drugs have been marketed for the treatment of COVID-19 infection in China, with the continuous updating of COVID-19 treatment regimens and the accessibility of drugs, the approved indications, applicable population, dosage, and route of administration of drug label are not sufficient to meet the real-world treatment needs. The off-label use of drugs indeed exists objectively, and its scientificity and rationality is in urgent need of discussion. This consensus aims to conduct evidence-based evaluation of off-label use in the treatment of COVID-19 infection based on the contents of domestic and foreign drug label registration, guideline, consensus, clinical research and other evidence-based medical evidence, and then the expert recommendation of off-label use in the treatment of COVID-19 infection will be formed by the expert group, so as to provide the basis for rational drug use for clinicians and further standardize the clinical application of off-label use of drugs for COVID-19 infection. |
